Trial Profile
Assessment of Safety,efficacy of Liposomal Amphotericin B (AmBisome) Vs Miltefosine 12 weeks therapy in patients with Post Kala-Azar Dermal Leishmaniasis (PKDL)-an observational pilot study
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 13 Nov 2018
Price :
$35
*
At a glance
- Drugs Amphotericin B liposomal (Primary) ; Miltefosine
- Indications Leishmaniasis
- Focus Therapeutic Use
- 13 Nov 2018 New trial record